Navigation Links
Zactima Receives Fast Track Designation By The FDA

ZACTIMA a product of AstraZeneca has been granted fast track designation by the US Food and Drug Administration (FDA). The drug also received the orphan drug designation // recently for treatment of anaplastic, medullary, follicular, locally advanced and metastatic medullary thyroid cancer. Following the approval, investigation of the drug in the treatment of medullary thyroid carcinoma is expected to accelerate further.

Medullary thyroid cancer accounts for 5 to 10% of all thyroid cancers. Surgery, nuclear medicine (treatment with radioactive iodine), hormonal manipulation, external beam radiotherapy (direction of radiation to kill cancer cells from outside the body) and chemotherapy represent some of the available treatment options.

Presently, there is no satisfactory chemotherapy regimen or other treatment modality for the cure of advanced thyroid cancer. Only those drugs, used for the treatment of severe diseases for which there is an unfulfilled medical need would be granted fast-track status by the FDA.

The fast track review by the FDA would be of immense help in the development of the drug and regulation of the submission process. The pharmaceutical company is currently involved in Phase II clinical trials of the drug, directed against metastatic or locally advanced medullary thyroid cancer.

The compound is believed to play a major role in the inhibition of the growth and spread of the thyroid cancer by participating in vital cell signalling pathways. Vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EFGR) participate in the inhibition pathway while REarranged during Transfection (RET) tyrosine kinases can accelerate the growth of the same.

If the treatment is found to be successful, then we might soon have a new treatment modality for the treatment of medullary thyroid cancer.


'"/>




Page: 1

Related medicine news :

1. Fifth US Patient Receives Artificial Heart
2. Northfield Labs Receives FDA Comments
3. British MPs Say Prostate Cancer Receives Low Priority in the NHS
4. Abbott Receives CE Mark Certification
5. East London Receives World Class New Private Hospital Facility
6. Brinda Karat Receives Legal Notice over Ramdev Issue
7. Quake-Hit Pakistan Receives 30 Field Hospitals From Cuba
8. Medtronic’s Insulin Pump Receives Regulatory Approva
9. Aurobindo Receives Approval from USFDA for anti-AIDS drug
10. Sunscreen Blocking UVA Radiation Receives Federal Approval
11. Eddie Thompson Receives Advanced Cancer Treatment
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many kids this ... by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids excited about ... ages; it is a non-competitive, non-timed event, which is all about having fun and ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the ... published author, William Nowers. Captain Nowers and his wife, Millie, have six children, ... in the Navy. Following his career as a naval aviator and carrier pilot, ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one ... an innovative new design of the shoulder pad. The shoulder pad provides optimal ... controlling your pain while using cold therapy. By utilizing ice and water that is ...
(Date:10/12/2017)... ... 2017 , ... HMP , a leader in healthcare events and education, today ... Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & ... award competition recognizes editorial and design excellence across a range of sectors. This year’s ...
(Date:10/12/2017)... ... October 12, 2017 , ... In the United States, single-family ... some states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the average ... extremely low property-tax rates, which contributes to the relatively lower cost of living ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... of 2017 on Tuesday, October 24, 2017. Lilly will ... the investment community and media to further detail the ... begin at 9 a.m. Eastern time. Investors, media and ... the conference call through a link that will be ...
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation ... and home sensors for real-time monitoring of patients with ... nonprofit organization focused on disruptive health solutions for rare ... system to record and integrate behavioral, cognitive, physiological and ... ...
(Date:9/23/2017)... HORSHAM, Pa. , Sept. 22, 2017 ... received a complete response letter from the U.S. Food ... (BLA) seeking approval of sirukumab for the treatment of ... response letter indicates additional clinical data are needed to ... of moderately to severely active RA. ...
Breaking Medicine Technology: